Pharmacological treatment of acute spinal cord injury: How do we build on past success?

Journal of Spinal Cord Medicine

Volumn 24, Issue 3, 2001, Pages 142-146

  Hall, Edward D ^a  

^a PFIZER INC   (United States)

Author keywords

Lipid peroxidation; Methylprednisolone; Neuroprotection; Neurorestoration; Nitric oxide synthase; Secondary injury process; Spinal cord injuries; Tirilazad

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CALPASTATIN; CLENBUTEROL; GLUCOCORTICOID; IMMUNOLOGIC AGENT; METHYLPREDNISOLONE; N [4 [4 [(3,4 DIHYDRO 6 HYDROXY 2,5,7,8 TETRAMETHYL 2H 1 BENZOPYRAN 2 YL)CARBONYL] 1 PIPERAZINYL]PHENYL] 2 THIOPHENECARBOXIMIDAMIDE; NALOXONE; NEUROPROTECTIVE AGENT; NITRIC OXIDE SYNTHASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOGENIC PROTEIN 1; PENICILLAMINE; REACTIVE OXYGEN METABOLITE; SCAVENGER; TACROLIMUS; TEMPOL; TIRILAZAD; UNCLASSIFIED DRUG; V 10367; PREGNANE DERIVATIVE;

APOPTOSIS; CELL TRANSPLANTATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG MEGADOSE; GASTROINTESTINAL HEMORRHAGE; GENE THERAPY; HUMAN; LIPID PEROXIDATION; NERVE CELL; NERVE CELL PLASTICITY; NERVE CELL STIMULATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; PNEUMONIA; REVIEW; SIDE EFFECT; SPINAL CORD INJURY; WOUND HEALING IMPAIRMENT; WOUND INFECTION; ACUTE DISEASE; METABOLISM; PHYSIOLOGY;

ACUTE DISEASE; HUMANS; LIPID PEROXIDATION; METHYLPREDNISOLONE; NEUROPROTECTIVE AGENTS; PREGNATRIENES; SPINAL CORD INJURIES;

EID: 0035462867     PISSN: 10790268     EISSN: None     Source Type: Journal    
DOI: 10.1080/10790268.2001.11753571     Document Type: Review

References (32)

1. Hall ED, Yonkers PA, Andrus PK, Cox JW, Anderson DK. Biochemistry and pharmacology of lipid antioxidants in acute brain and spinal cord injury. J Neurotrauma. 1992;9(suppl 2):425-442.
2. Hall ED, Wolf DL. A pharmacological analysis of the pathophysiological mechanisms of posttraumatic spinal cord ischemia. J Neurosurg. 1986;64:951-961.
3. Bracken MB, Shepard MJ, Collins WF, et al. A randomized controlled trial of methylprednisolone or naloxone in the treatment of acute spinal cord injury. N Engl J Med. 1990;322:1405-1411.
4. Bracken MB, Shepard MJ, Holford TR, et al. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury: results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial: National Acute Spinal Cord Injury Study. JAMA. 1997;277:1597-1604.
5. Hall ED, Braughler, JM. Acute effects of intravenous glucocorticoid pretreatment on the in vitro peroxidation of cat spinal cord tissue. Exp Neurol. 1981;73:321-324.
6. Hall ED, Braughler JM. Effects of intravenous methylprednisolone on spinal cord lipid peroxidation and (Na+ + K+)-ATPase activity: dose-response analysis during 1 st hour after contusion injury in the cat. J Neurosurg. 1982;57:247-253.
7. Young W, Flamm ES. Effects of high dose corticosteroid therapy on blood flow, evoked potentials, and extracellular calcium in experimental spinal injury. J Neurosurg. 1982;57:667-673.
8. Hall ED, Wolf DL, Braughler JM. Effects of a single large dose of methylprednisolone sodium succinate on experimental posttraumatic spinal cord ischemia. J Neurosurg. 1984;61:124-130.
9. Anderson DK, Means ED. Microvascular perfusion and metabolism in injured spinal cord after methylprednisolone treatment. J Neurosurg. 1982;56:106-113.
10. Braughler JM, Hall ED. Lactate and pyruvate metabolism in injured cat spinal cord before and after a single large intravenous dose of methylprednisolone. J Neurosurg. 1983;59:256-261.
11. Braughler JM, Hall ED. Effects of multidose methylprednisolone sodium succinate administration on injured cat spinal cord neurofilament degradation and energy metabolism. J Neurosurg. 1984;61:290-295.
12. Hall ED. Neuroprotective pharmacology of methylprednisolone: a review. J Neurosurg. 1992;76:13-22.
13. Braughler JM, Hall ED. Uptake and elimination of methylprednisolone from contused spinal cord following intravenous injection of the sodium succinate ester. J Neurosurg. 1983;58:538-542.
14. Braughler JM, Hall ED, Means ED, Waters, TR, Anderson, D.K. Evaluation of an intensive methylprednisolone sodium succinate dosing regimen in experimental spinal cord injury. J Neurosurg. 1987;67:102-105.
15. Bracken MB, Shepard MJ, Collins WF, et al. Methylprednisolone or naloxone treatment after acute spinal cord injury: 1 year follow-up data. J Neurosurg. 1992;76:23-31.
16. Hall ED, Yonkers PA, Taylor BA, Sun FF. Lack of effect of post-injury treatment with methylprednisolone or tirilazad mesylate on eicosanoid levels in the acutely injured cat spinal cord. J Neurotrauma. 1995;12:245-256.
17. Anderson DK, Braughler JM, Hall ED, Waters TR, McCall JM, Means ED. Effect of treatment with U-74006F on the neurological outcome following experimental spinal cord injury. J Neurosurg. 1988;69:562-567
18. Anderson DK, Hall ED, Braughler JM, McCall JM, Means ED. Effect of delayed administration of U-74006F (tirilazad mesylate) on recovery of locomotor function following experimental spinal cord injury. J Neurotrauma. 1991;8:187-192.
19. Hall ED, McCall JM, Means ED. Therapeutic potential of the lazaroids (21-aminosteroids) in acute central nervous system trauma, ischemia and subarachnoid hemorrhage. Adv Pharmacol. 1994;28:221-268.
20. Beckman JS. The double-edged role of nitric oxide in brain function and superoxide-mediated injury. J Dev Physiol. 1991;15:53-59.
21. Hall ED, Kupina NC, Althaus JS. Peroxynitrite scavengers for the acute treatment of traumatic brain injury. Ann NY Acad Sci. 2000;890:462-468.
22. Carroll, RT, Galatsis P, Borosky S, et al. 4-Hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl (Tempol) inhibits peroxynitrite-mediated phenol nitration. Chem Res Toxicol. 2000;13:294-300.
23. Chabrier P-E, Auguet M, Spinnewyn B, et al. BN 80933, a dual inhibitor of neuronal nitric oxide synthase and lipid peroxidation: a promising neuroprotective strategy. Proc Natl Acad Sci. 1999;96:10824-10829.
24. Yuen P-W, Wang KKW. Therapeutic potential of calpain inhibitors in neurodegenerative disorders. Exp Opin Invest Drugs. 1996;5:1291-1304.
25. Beattie MS, Farooqui AA, Bresnahan JC. Review of the current evidence for apoptosis after spinal cord injury. J Neurotrauma. 2000;17:915-925.
26. Resnick DK, Graham SH, Dixon CE, Marion DW. Role of cyclooxygenase 2 in acute spinal cord injury. J Neurotrauma. 1998;15:1005-1013.
27. Zeman RJ, Feng Y, Peng H, Etlinger JD. Clenbuterol, a beta(2)-adrenoceptor agonist, improves locomotor and histological outcomes after spinal cord contusion in rats. Exp Neurol. 1999;159:267-273.
28. Schallert T, Fleming SM, Leasure JL, Tillerson JL, Bland ST. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology. 2000;39:777-787.
29. Madsen JR, MacDonald P, Irwin N. Tacrolimus (FK506) increases neuronal expression of GAP-43 and improves functional recovery after spinal cord injury in rats. Exp Neurol. 1998;154:673-683.
30. Gold BG, Zeleny-Pooley M, Chaturvedi P, Wang MS. Oral administration of a non-immunosuppressant FKBP-12 ligand speeds nerve regeneration. Neuroreport. 1998;9:553-538.
31. Fournier AE, Strittmatter SM. Repulsive factors and axon regeneration in the CNS. Curr Opin Neurobiol. 2001;11:89-94.
32. Zeidman SM, Ling GS, Ducker TB, Ellenbogen RG. Clinical applications of pharmacologic therapies for spinal cord injury. J Spinal Disorders. 1996;9:367-380.